Abstract: PET/CT imaging using 68Ga-labeled somatostatin analogs has become a popular noninvasive diagnostic modality in the workup of patients with neuroendocrine tumors. A 65-year-old man with pancreatic neuroendocrine tumor with confirmed liver metastases on conventional imaging underwent restaging 68Ga-DOTANOC PET/CT to monitor response to cold octreotide therapy. Previous PET/CT had shown presence of multiple liver and skeletal metastases along with a primary pancreatic tumor showing intense tracer uptake. The present PET/CT study showed an increase in number and uptake of the metastatic lesions suggestive of progressive disease resulting in the appearance of a superscan.
From the Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Received for publication December 17, 2011; revision accepted April 12, 2012.
Conflicts of interest and sources of funding: none declared.
Reprints: Rakesh Kumar, MD, Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, Indica. E-mail: email@example.com.